A new way to understand oral cancer risk
The REASON Score: An Epigenetic And Clinicopathologic Score to Predict Risk of Poor Survival in Early Stage Oral Squamous Cell Carcinoma Patients
['FUNDING_R01'] · LOMA LINDA UNIVERSITY · NIH-11103260
This project aims to create a better tool to help doctors understand the risk of early-stage oral cancer returning or getting worse, so patients can receive the most effective treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LOMA LINDA UNIVERSITY (nih funded) |
| Locations | 1 site (Loma Linda, UNITED STATES) |
| Trial ID | NIH-11103260 on ClinicalTrials.gov |
What this research studies
Many people with early-stage oral cancer face uncertain outcomes, and current methods don't always predict who needs more aggressive treatment. This project is developing a special "REASON Score" that combines information from your tumor's biology with other clinical details. By using this score, doctors hope to identify patients at higher risk, allowing them to tailor treatments more precisely and improve chances of survival. This could mean fewer patients receive unnecessary harsh treatments, while those who truly need them get them sooner.
Who could benefit from this research
Good fit: This research is focused on patients diagnosed with early-stage oral squamous cell carcinoma.
Not a fit: Patients with advanced-stage oral cancer or other types of cancer may not directly benefit from this specific risk assessment tool.
Why it matters
Potential benefit: If successful, this tool could help doctors choose the best treatment plan for each patient with early-stage oral cancer, potentially improving survival rates and reducing side effects from overtreatment.
How similar studies have performed: The researchers have already developed an initial version of this risk score that showed strong predictive performance in earlier work.
Where this research is happening
Loma Linda, UNITED STATES
- LOMA LINDA UNIVERSITY — Loma Linda, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VIET, CHI T. — LOMA LINDA UNIVERSITY
- Study coordinator: VIET, CHI T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Induction, Cancers